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Summary. To clarify whether advanced colorectal car- 
cinomas and tumor-neighboring mucosa simultaneously 
produce both Bcl-2 protein and gut neurohormonal 
polypeptides andlor amines, and the interrelationship of 
these phenomenon, we studied retrospective analysis of 
Bcl-2 protein production and neuroendocrine character- 
istics in 52 cases of advanced colorectal carcinoma and 
surrounding mucosa. All of the tumor-neighboring 
mucosa presented hyperplasia. The rates of enhanced 
immunoreactivity of the tumor-neighboring mucosa and 
of positive immunoreactivity of the carcinomas against 
human Bcl-2 protein and against human vasoactive 
intestinal polypeptide, pancreatic polypeptide and 
somatostatin were 78.8% and 94.2%, 82.7% and 59.6%, 
78.8% and 67.3%, and 88.5% and 84.6% respectively. 
Double immunostaining for Bcl-2 protein and each 
peptide hormone revealed simultaneous expression. In 
contrast,  that of tumor-neighboring mucosa and 
carcinomas to serotonin and chromogranin-A and to 
argyrophilia were 11.5% and 1.9%, 32.7% and 17.3%, 
and 26.9% and 21.2%, respectively. We concluded that 
tumor-neighboring crypt cells displayed not only 
hyperplasia but also neuroendocrine characteristics and 
that enhanced Bcl-2 protein immunoreactivity correlated 
with tumor occurrence in the wall of the colorectum. The 
production of Bcl-2 protein by tumor cells and tumor- 
neighboring crypt cells indicates that the bcl-2 proto- 
oncogene may act not only as an inhibitor of apoptosis 
but also as an inducer of neuroendocrine differentiation 
from the latent characteristics of the endodermal stem 
cell. 
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Introduction 
Colorectal epithelium composed of columnar, 
mucous, and endocrine crypt cells originates from 
multipotential endodermal stem cells at the base of the 
intestinal crypts (Chang et al., 1971) and the endocrine 
cancer cells found in gastrointestinal carcinomas develop 
by amphocrine differentiation during carcinogenesis in 
the same tumor (Cox and Pierce, 1982; I rk land ,  1988). 
A recent study by us demonstrated that colorectal 
carcinomas exhibit not only multiendocrine characteris- 
t ics producing various types of neurohormonal 
polypeptide, but also amphocrine characteristics of 
different grades and, interestingly, most tumor- 
neighboring crypt cells possess those characteristics also 
(Ohmori et al., 1996). 
Most recently, Wang and Reed (1998) reviewed the 
function of Bcl-2 protein and its mechanisms together 
with several cellular and viral homologue with particular 
interest in the regulation of the programemd cell death 
(apoptosis) pathway in nomalcy and disease, and 
suggested that dysregulation of the process probably 
plays a major role in carcinogenesis, autoimmune 
disease and AIDS. Furthermore, there have been a 
number of studies suggesting that Bcl-2 protein 
expression has a close correlation with neuroendocrine 
differentiation in the development of enterochromaffin- 
like cell gastric carcinoids (Azzoni et al., 1996), small 
cell lung carcinoma (Jing et al., 1996), and neuro- 
blastoma (Krajewski et al., 1995) and its cell line 
(Hanada et al., 1993), while others suggest that high 
levels of Bcl-2 protein can render cells remarkably 
resistant to killing by a wide variety of cytotoxic drugs 
(Fannidi et al., 1992; Miyashita and Reed, 1992; Hanada 
et al., 1993). The bcl-2 proto-oncogene (bcl-2 gene) was 
first  detected in follicular B cell  lymphomas 
accompanied by the over-expression of its 26 KD 
protein (Bcl-2 protein) (Tsujimoto and Croce, 1986), and 
the bcl-2 gene initially plays an unambiguous role in 
prolonging cell survival by blocking programmed cell 







